Merrimack Pharmaceuticals

$7.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (+1.81%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell MACK and other stocks, options, and ETFs commission-free!

About MACK

Merrimack Pharmaceuticals, Inc. Common Stock, also called Merrimack Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. The listed name for MACK is Merrimack Pharmaceuticals, Inc. Common Stock.

CEO
Gary L. Crocker
Employees
—
Headquarters
Cambridge, Massachusetts
Founded
1993
Market Cap
103.24M
Price-Earnings Ratio
—
Dividend Yield
6.46
Average Volume
218.37K
High Today
$7.51
Low Today
$7.12
Open Price
$7.19
Volume
33.14K
52 Week High
$9.45
52 Week Low
$1.49

MACK Earnings

-$0.71
-$0.47
-$0.22
$0.02
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

NUS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure